We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CNCR market cap is 12.78M. The company's latest EPS is USD -5.7713 and P/E is -2.77.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End August 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 224k | 177k | 190k | 153k | 70k |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | -13.61M | 10.92M | 5.7M | -17.58M | -4.62M |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End August 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 35.2M | 40.32M | 44.47M | 23.25M | 9.65M |
| Total Liabilities | 1.01M | 26k | 29k | 17k | 6k |
| Total Equity | 34.2M | 40.29M | 44.44M | 23.23M | 9.64M |
| Market Cap | 12.78M |
| Price to Earnings Ratio | -2.77 |
| Price to Sales Ratio | 182.74 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 1.33 |
| Dividend Yield | - |
| Shares Outstanding | 800k |
| Average Volume (1 week) | 6.85k |
| Average Volume (1 Month) | 15.43k |
| 52 Week Change | 25.16% |
| 52 Week High | 18.00 |
| 52 Week Low | 9.22 |
| Spread (Intraday) | 7.94 (39.94%) |
| Company Name | ETF Series Solutions Trust Range Cancer Therapeutics |
| Address |
615 east michigan st milwaukee, wisconsin 53202 |
| Website | https://www.loncarfunds.com |
| Industry | mgmt invt offices, open-end (6722) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
